Vimentin 3 Expression in Prostate Cancer Cells

Köditz, Barbara; Stog, Andreas; Göbel, Heike; Heidegger, Isabell; Fries, Jochen W.U.; Heidenreich, Axel; Brandenstein, Melanie von

doi:10.21873/anticanres.14762

Cited by 2 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…higher than VIM-FL expression in the nucleus. As recently described, the expression of VIM3 seems to be of great importance for prostate cancer cells (13). Carcinoma cells which are more aggressive have higher levels of VIM3 (10).…”

Section: Discussionmentioning

confidence: 71%

“…The knockdown of VIM3 led to down-regulation of miR-371a-3p compared to cells treated with EDN1 for all prostate cancer cell lines (Figure 3D). The high expression of miR-371a-3p after EDN1 treatment can be explained by the fact that EDN1 induces VIM3 expression, which results in higher miR-371a-3p expression (13). However, a slight increase of miR-371a-3p expression was observed after VIM3 siRNA treatment compared to the siRNA control cells.…”

Section: Discussionmentioning

confidence: 96%

“…Nuclear extracts were isolated from all cell lines which were previously treated with 50 nM endothelin 1 (EDN1) or which received no treatment (control). EDN1-treated cells were used next to untreated control cells since it is known that EDN1 induces overexpression of VIM3 (13,43). Nuclear extracts (20 μg) of the cells were incubated VIM3 antibody for the supershift, followed by an incubation with the specific palindromic oligonucleotides for the hypothesized promoter region of pri-miR-371a-3p.…”

Section: Discussionmentioning

confidence: 99%

“…Our research group recently analyzed the effects of endothelin 1 (EDN1) on the expression of VIM3 (13). EDN1 was first described in 1988 as a vasoconstrictor peptide and is currently known as a multifunctional protein in cancer (14).…”

mentioning

confidence: 99%

“…Since it is known that elevated EDN1 levels in patients with prostate cancer are associated with higher metastatic potential and that the levels of EDN1 in cancer cells correlate with tumor progression, we were interested whether elevated EDN1 levels also correlate with higher VIM3 levels (15,16). In previous work, we showed that prostate cancer cells migrated faster under stimulation with EDN1 and that EDN1 induced VIM3 expression (13).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p

NOHL,

BEHRING,

KAMERI

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: It is not possible to differentiate prostate carcinomas sufficiently to ensure that every patient receives the right therapy. New molecular markers are needed. Our objective was to identify a complex consisting of vimentin variant 3 (VIM3), autophagy-related protein 7 (ATG7) and tumor protein p53 (TP53) in prostate cancer cells and its effect on microRNA (miR)-371a-3p. Materials and Methods: Prostate cancer cell lines (PC3, DU145, LNCaP) and the benign prostatic hyperplasia cell line BPH-1 were cultured in growth medium for 24 h, then stimulated with endothelin 1 (EDN1) (50 nM) and withaferin A (2 nM) for 24 h. Cell extracts were then analyzed by western blot. The localization of VIM3, ATG7 and TP53 in the nucleus was demonstrated with immunofluorescence staining and complex formation was demonstrated by immunoprecipitation. Cancer cell migration was analyzed with a scratch assay and agarose drop analysis. The binding of the complex to the promoter of pri-miR-371a-3p was analyzed with a non-radioactive electrophoretic mobility shift assay. VIM3 knockdown using small interfering RNA and quantitative real-time polymerase chain reaction for miR-371a-3p were performed. Results: The complex was present in the nucleus of prostate cancer cells and in the BPH-1 cell line. EDN1 increased the levels of the complex partners and cell migration, whereas withaferin A reduced the levels of the complex partners and migration. The complex bound to the promoter of pri-miR-371a-3p and might be involved in its transcription. Transfection with miR-371a-3p increased migration of prostate cancer cells. VIM3 knockdown reduced miR-371a-3p expression. Conclusion: The VIM3-ATG7-P53 complex, with its stimulatory effect on miR-371a-3p, may have the potential to be a marker for improved differentiation between prostate carcinomas, allowing tailored therapy. Recently, vimentin variant 3 (VIM3; PubMed: ACA06103.1) was discovered as a potential surrogate marker for prostate cancer (10). VIM3 is related to vimentin, an intermediate filament in mesenchymal and muscle cells, but with the important difference that it lacks the C-terminal ending of full-2407

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations